Using SPECT/CT to evaluate kidney tumors
SPECT/CT for the Characterization of Renal Masses: Impact on Clinical Decision Making
Jonsson Comprehensive Cancer Center · NCT03996850
This study is testing if a special type of imaging called SPECT/CT can help doctors make better treatment decisions for patients with kidney tumors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Jonsson Comprehensive Cancer Center (other) |
| Drugs / interventions | radiation |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT03996850 on ClinicalTrials.gov |
What this trial studies
This observational trial investigates the effectiveness of technetium Tc-99m sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) in guiding clinical decisions for patients with kidney tumors. The study aims to assess how SPECT/CT impacts management decisions, particularly for tumors of varying sizes, and evaluates its sensitivity and specificity in identifying oncocytic renal masses. Patients will receive the SPECT/CT imaging after an intravenous injection of the tracer and will be followed for six months to monitor outcomes and treatment decisions.
Who should consider this trial
Good fit: Ideal candidates include patients with a new diagnosis of a solid renal tumor measuring between 1.5-5.0 cm and who are not in need of urgent surgical intervention.
Not a fit: Patients with multiple solid renal tumors or a prior diagnosis of kidney cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a less invasive method for accurately diagnosing kidney tumors, leading to better-informed treatment decisions.
How similar studies have performed: Other studies have shown promising results with similar imaging techniques, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Performance status Eastern Cooperative Oncology Group (ECOG) \< 2. * Life expectancy (\> 1 year). * New diagnosis of a renal tumor (within past 3 months). * Measurable, predominantly (\> 80%) solid renal neoplasm between 1.5-5.0 cm. * Lesion concerning for kidney cancer bases on a contrast-enhanced CT or magnetic resonance imaging (MRI). * No definitive evidence of metastatic disease. * Does not require urgent surgical treatment. * Candidate for surgical, ablative, and surveillance approach. * Willingness to obtain more information to aid decision-making. * Understanding and willingness to provide consent. Exclusion Criteria: * Presence of multiple solid renal tumors. * A prior needle biopsy of the mass resulting in histologic diagnosis. * A prior diagnosis of kidney cancer. * Presence of an active, untreated, non-renal malignancy. * History of bleeding diathesis or recent bleeding episode. * Prior surgery or radiation therapy to the kidney. * Unwillingness to fill out questionnaires.
Where this trial is running
Los Angeles, California
- UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California, United States (RECRUITING)
Study contacts
- Principal investigator: Brian Shuch — UCLA / Jonsson Comprehensive Cancer Center
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Kidney Neoplasm, Renal Mass